PSTX — Poseida Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $927.88m
- $755.94m
- $64.70m
- 30
- 13
- 90
- 41
Annual cashflow statement for Poseida Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -86.5 | -130 | -125 | -64 | -123 |
| Depreciation | |||||
| Non-Cash Items | 11.3 | 8.24 | -2.29 | 18.3 | 11.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.47 | 5.62 | 20.2 | 13.7 | 14.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -64.5 | -113 | -103 | -26.8 | -92.2 |
| Capital Expenditures | -5.16 | -16.9 | -2.63 | -3.92 | -3.07 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -37.3 | -188 | 225 | -199 | 42.2 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -42.5 | -204 | 222 | -203 | 39.1 |
| Financing Cash Flow Items | 4.59 | 3.83 | 0 | -1.45 | -0.494 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 164 | 314 | 2.52 | 105 | 16.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 57.4 | -3.82 | 122 | -125 | -36.9 |